Search

Introduction: Despite significant improvements in early detection and treatment, the disparities seen among cancer patients have persisted Sepsis and Deep Vein Thrombosis (DVT) / Pulmonary Embolus (PE) remain leading causes of death among cancer patients Emergency departments (ED) serve as critical entry points into the inpatient acute care setting The novel SARS-COV2 virus has intensified the risk facing these patients The purpose of this study is to characterize the mortality and morbidity rates in cancer patients admitted through the ED of an urban academic hospital Methods: Retrospective cohort analysis of cancer patients seen in the ED in 2019 Billing data was used to identify the cohort of cancer patients using the terms “Neoplasm”, “Malignant”, “Malignancy” or “Cancer” Excluded were terms like benign, family history or screening The final cohort included patients with both active cancer as well as those with a history of cancer Results: Of the 27,327 unique patients seen in the ED, 1,597 (5 8%) were cancer patients, accounting for 3,135 (6 9%) visits Of the total of 133 deaths seen in patients admitted through the ED, 29 (21 8%) were in cancer patients This represents a mortality rate of 9 3 per 1000 visits (18 2 per 1000 patients) This is in contrast to an overall mortality rate of 2 9 per 1000 visits (4 9 per 1000 patients) Among the cancer cohort, the mortality rate increased to 20% (7/35) with a sepsis diagnosis and 4 8% (2/41) with a diagnosis of DVT/PE Conclusion: Understanding the significant risk associated with cancer patients requiring inpatient admission highlights the needs for screening protocols for early detection of life-threatening conditions such as sepsis and DVT/PE upon entry into the inpatient setting, especially among populations at risk for poor outcomes

Rishi Agarwal,1,2 Paramveer Saluja,1 Angela Pham,3 Karen Ledbetter,3 Sukhveer Bains,3 Seema Varghese,3 John Clements,1 Young H Kim41Synergy Medical Education Alliance, Michigan State University College of Human Medicine, Saginaw, Michigan, USA; 2MD Anderson Cancer Center, Houston, Texas, USA; 3Michigan State University, Saginaw, Michigan, USA; 4Seton Cancer Institute, Saginaw, Michigan, USAIntroduction: The current standard for treating operable early stage non-small cell lung cancer is surgical resection and for inoperable cases it is external beam radiotherapy. Lung functions are adversely affected with both the above treatments. CyberKnife treatment limits radiation damage by tracking targets moving with each breath. The effect of CyberKnife treatment on pulmonary function tests has not been well documented.Methods: Lung cancer patients who underwent CyberKnife treatment and had pre- and post-treatment pulmonary function tests were included. Paired t-tests were conducted. We also conducted subgroup analysis.Results : Thirty-seven patients were included. Median age was 73 years. No statistical difference between mean pre- and post-CyberKnife pulmonary function tests was found.Discussion: We observed that CyberKnife better preserves lung function status compared to current standards of care. It has shown to have very minimal side effects.Keywords: non-small cell lung cancer, radiation pneumonitis, radiotherapy, pulmonary function tests